Be the first person to write a business review for Brown Gibbons Lang & Company LLC

Bruckmann, Rosser, Sherrill & Co., L.L.C. ("BRS") is a New York-based private equity investment firm with approximately $1.4 billion in funds under management. Founded in 1995 by former senior executives of Citicorp Venture Capital, Ltd., BRS specializes in management buyouts and recapitalizations of high quality, middle market companies with strong market positions and/or growth potential. BRS's philosophy is to back the management of its portfolio companies, allowing them operational freedom with long-term equity incentives and support. BRS provides expertise to portfolio companies in the areas of financing, acquisitions and strategic long-term planning focused upon realization of value.The founders of BRS have had extensive experience since the mid 1980's in initiating, negotiating, financing, closing and overseeing numerous private equity investments in diverse industries throughout a range of economic cycles and financial market conditions. They have undertaken management buyouts of public companies, private companies, and divisions of larger companies; recapitalizations of closely held companies providing both liquidity and continual ownership to existing owners; build-ups of significant enterprises through acquisitions; and equity investments in growth companies.

Burns, Philp & Company Pty Limited and its subsidiaries engage in the manufacture, marketing, and distribution of food ingredients, and consumer branded food and related products primarily in New Zealand. Its products include snack foods, such as salty and nutritious snacks; baking products, such as packaged loaf bread, other baked goods, and frozen meals; and spreads and oils, including fats and oils, bulk and retail flour, margarine and spreads, cake mixes, mayonnaise, dressings, chickens, and ice cream. Burns, Philp & Company’s customers include supermarket chains and convenience stores in New Zealand.

Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $950 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development.Burrill is also the sponsor and facilitator of several leading annual industry conferences and publishes the seminal annual report on the state of the biotechnology industry. This combination of resources and capabilities has helped Burrill develop a unique and highly effective platform for finding and making outstanding life science investments.G. Steven Burrill founded Burrill & Company as a logical extension of his 40-year involvement in the growth and prosperity of the biotechnology industry. Mr. Burrill has been an active advisor and catalyst in some of the industry's most notable companies and transactions. Mr. Burrill's close involvement and respected position within the industry has positioned the firm as a prominent deal-maker and facilitator of industry partnerships and alliances, all of which fosters a robust deal flow. Further contributing to this deal flow are: the scientific and business networks of its investment team; the Advisory Boards; the strategic and financial network of its limited partners; and the close relationships developed with numerous life science companies and management as a result of Burrill's visibility, reputation, and the firm's partnering and alliance work.

Cabot Square Capital was founded in 1996. Cabot Square Capital invests capital in small and mid-sized companies in growing markets in the UK and Western Europe. It also specializes in startup business and companies in a state of expansion or turnaround. The firm currently offers customers its Cabot Square Capital Partners II, with some $200 million ($320 million) of committed capital, and its third fund, CS Capital Partners III, with approximately $300 million ($480 million) of committed capital. The firm typically takes majority control positions in its acquisitions and sees its role as a value-added partner.

Calera Capital was founded in 1991 and is headquartered in San Francisco, California. Calera Capital is a private equity firm specializing in investments in public or private middle market companies, family-controlled enterprises, and corporate divestitures. It seeks to invest in buyouts and PIPES. The firm invests across a wide variety of industries, including building and forest products, food and consumer products, healthcare and medical devices, distribution and business services, specialty packaging, financial services, electrical products and industrial manufacturing. The firm considers investments in corporate spin-offs, take-private transactions, leveraged re-capitalizations of privately held companies, restructurings, and companies seeking capital to facilitate growth or acquisitions. It focuses on companies with enterprise values of up to $1 billion, typically deploying a minimum of $75 million in each transaction.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.